Effects of melanocortin 1 receptor agonists in experimental nephropathies.

Nephrotic syndrome, characterized by massive proteinuria, is caused by a large group of diseases including membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). Although the underlying mechanisms are beginning to unravel, therapy is unspecific and far from efficient. It has been...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Annika Lindskog Jonsson, Anna Granqvist, Johannes Elvin, Martin E Johansson, Börje Haraldsson, Jenny Nyström
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6ca5e8f53f5a4a4f990af4006af73e9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ca5e8f53f5a4a4f990af4006af73e9c
record_format	dspace
spelling	oai:doaj.org-article:6ca5e8f53f5a4a4f990af4006af73e9c2021-11-18T08:34:44ZEffects of melanocortin 1 receptor agonists in experimental nephropathies.1932-620310.1371/journal.pone.0087816https://doaj.org/article/6ca5e8f53f5a4a4f990af4006af73e9c2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24498203/?tool=EBIhttps://doaj.org/toc/1932-6203Nephrotic syndrome, characterized by massive proteinuria, is caused by a large group of diseases including membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). Although the underlying mechanisms are beginning to unravel, therapy is unspecific and far from efficient. It has been suggested that adrenocorticotropic hormone (ACTH) has beneficial effects in patients with MN and possibly in other nephrotic diseases. We have previously reported that ACTH may act directly on podocytes through the melanocortin 1 receptor (MC1R). In the present study, we evaluate the effect of highly specific MC1R agonists in two different nephrotic disease models. Experimental MN: Passive Heymann nephritis (PHN) was induced in rats that were treated for four weeks with MS05, a selective MC1R agonist, or saline. The degree of albuminuria was significantly reduced over time and the effect was sustained one week after treatment withdrawal (p<0.05). Experimental FSGS: Based on a dose-response study, two doses of adriamycin were used for induction of nephropathy in Balb/c mice. Mice were treated with either a synthetic MC1R agonist (BMS-470539), with α-melanocyte stimulating hormone (α-MSH) or with saline. There was no beneficial effect of treatment. In summary, MC1R agonists reduce albuminuria and improve morphology in experimentally induced MN whereas they have no effect in experimental FSGS. The results illustrate the differences in these podocytopathies in terms of signaling mechanisms underlying proteinuria, and progression of disease.Annika Lindskog JonssonAnna GranqvistJohannes ElvinMartin E JohanssonBörje HaraldssonJenny NyströmPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e87816 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Annika Lindskog Jonsson Anna Granqvist Johannes Elvin Martin E Johansson Börje Haraldsson Jenny Nyström Effects of melanocortin 1 receptor agonists in experimental nephropathies.
description	Nephrotic syndrome, characterized by massive proteinuria, is caused by a large group of diseases including membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). Although the underlying mechanisms are beginning to unravel, therapy is unspecific and far from efficient. It has been suggested that adrenocorticotropic hormone (ACTH) has beneficial effects in patients with MN and possibly in other nephrotic diseases. We have previously reported that ACTH may act directly on podocytes through the melanocortin 1 receptor (MC1R). In the present study, we evaluate the effect of highly specific MC1R agonists in two different nephrotic disease models. Experimental MN: Passive Heymann nephritis (PHN) was induced in rats that were treated for four weeks with MS05, a selective MC1R agonist, or saline. The degree of albuminuria was significantly reduced over time and the effect was sustained one week after treatment withdrawal (p<0.05). Experimental FSGS: Based on a dose-response study, two doses of adriamycin were used for induction of nephropathy in Balb/c mice. Mice were treated with either a synthetic MC1R agonist (BMS-470539), with α-melanocyte stimulating hormone (α-MSH) or with saline. There was no beneficial effect of treatment. In summary, MC1R agonists reduce albuminuria and improve morphology in experimentally induced MN whereas they have no effect in experimental FSGS. The results illustrate the differences in these podocytopathies in terms of signaling mechanisms underlying proteinuria, and progression of disease.
format	article
author	Annika Lindskog Jonsson Anna Granqvist Johannes Elvin Martin E Johansson Börje Haraldsson Jenny Nyström
author_facet	Annika Lindskog Jonsson Anna Granqvist Johannes Elvin Martin E Johansson Börje Haraldsson Jenny Nyström
author_sort	Annika Lindskog Jonsson
title	Effects of melanocortin 1 receptor agonists in experimental nephropathies.
title_short	Effects of melanocortin 1 receptor agonists in experimental nephropathies.
title_full	Effects of melanocortin 1 receptor agonists in experimental nephropathies.
title_fullStr	Effects of melanocortin 1 receptor agonists in experimental nephropathies.
title_full_unstemmed	Effects of melanocortin 1 receptor agonists in experimental nephropathies.
title_sort	effects of melanocortin 1 receptor agonists in experimental nephropathies.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/6ca5e8f53f5a4a4f990af4006af73e9c
work_keys_str_mv	AT annikalindskogjonsson effectsofmelanocortin1receptoragonistsinexperimentalnephropathies AT annagranqvist effectsofmelanocortin1receptoragonistsinexperimentalnephropathies AT johanneselvin effectsofmelanocortin1receptoragonistsinexperimentalnephropathies AT martinejohansson effectsofmelanocortin1receptoragonistsinexperimentalnephropathies AT borjeharaldsson effectsofmelanocortin1receptoragonistsinexperimentalnephropathies AT jennynystrom effectsofmelanocortin1receptoragonistsinexperimentalnephropathies
_version_	1718421627308343296

Effects of melanocortin 1 receptor agonists in experimental nephropathies.

Ejemplares similares